Search results
Results from the WOW.Com Content Network
Triple-negative is sometimes used as a surrogate term for basal-like. [2] Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers.
The first was for breast cancer, [9] another was for squamous-cell lung cancer. [10] Preliminary results in June 2009 on triple-negative breast cancer were promising. [11] Later results showed increased median survival of triple-negative breast cancer patients from 7.7 to 12.2 months. [12] [13] [14]
Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective. [3] It has also been used to treat triple-negative breast cancer.
Triple-negative breast cancer (up to 15% of cases) and inflammatory breast cancer (up to 5% of cases) are particularly aggressive and have relatively poor prognoses. [ 87 ] [ 88 ] Those with triple-negative breast cancer have an overall five-year survival rate of 77% – 91% for those whose tumors are confined to the breast; 12% for those with ...
In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. [1] Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence. [2]
The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]
[27] it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer. [28] Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [29] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 ...
This is a list of major breast cancer cell lines that are primarily used in breast cancer research. [Notes 1] List of cell lines. Cell line Primary tumor